Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
· Tumor responses observed in 7 out of 20 evaluable patients, resulting in best objective response rate (ORR) of 35% · Systemic effects observed in multiple patients, including two examples where a non-injected lesion completely regressed · An online presentation by Targovax’s management will take place at 10:00 CET 2 December 2020 (details below)Oslo, Norway, 1 December 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the combination of ONCOS-102 and pembrolizumab (